Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
110 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2014', provides an overview of the Human papillomavirus (HPV) Associated Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Human papillomavirus (HPV) Associated Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Human papillomavirus (HPV) Associated Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 11 Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 12 Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 13 Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 15 Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 19 Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 21 Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 22 3SBio Inc. 22 Abivax 23 Antigen Express, Inc. 24 Bionor Pharma ASA 25 Cancer Therapeutics CRC Pty Ltd 26 Etubics Corporation 27 EyeGene, Inc. 28 Formune S.L. 29 Genexine, Inc. 30 Gliknik, Inc. 31 iBio, Inc. 32 Inovio Pharmaceuticals, Inc. 33 MedImmune, LLC 34 Merck & Co., Inc. 35 Onconova Therapeutics, Inc. 36 Prima BioMed Ltd. 37 Sirnaomics, Inc. 38 THERAVECTYS SA 39 Transgene SA 40 Vaccibody AS 41 ViroStatics, srl 42 Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 ABX-318 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AEH-10p - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cell Therapy to Target (HPV) E6 Protein for Papillomavirus Associated Cancers - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 durvalumab + tremelimumab - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 EDA-HPVE7 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 EG-HPV - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Gene Therapy for Papillomavirus Associated Cervical Carcinoma - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 GL-0810 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 GX-188E - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 HPV Vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 human papillomavirus vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 human papillomavirus vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 human papillomavirus vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 INO-3106 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 INO-3112 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 P16-37-63 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 rigosertib sodium - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SSS-08 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 STP-909 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 STP-911 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Subunit Vaccine for Cervical Cancer - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 TG-4001 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 V-503 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Vacc-HPV - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Vaccine for HPV Associated Cancer - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Vaccine for HPV Associated Cancers - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Vaccine for HPV Associated Cancers - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Vaccine for HPV Associated Skin Cancer - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Vaccine for HPV-Head and Neck Cancer - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 VB-1016 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 97 Human papillomavirus (HPV) Associated Cancer - Dormant Projects 105 Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 106 Featured News & Press Releases 106 Mar 05, 2014: Generex Subsidiary Antigen Express Receives Patents for Vaccines Targeting HPV Induced Cancers and Influenza 106 Nov 04, 2013: Merck's Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study 106 Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 108 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 110 Disclaimer 110
List of Tables Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H2 2014 11 Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 15 Comparative Analysis by Late Stage Development, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2014 21 Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H2 2014 22 Human papillomavirus (HPV) Associated Cancer - Pipeline by Abivax, H2 2014 23 Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2014 24 Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2014 25 Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 26 Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2014 27 Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2014 28 Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2014 29 Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2014 30 Human papillomavirus (HPV) Associated Cancer - Pipeline by Gliknik, Inc., H2 2014 31 Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2014 32 Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 33 Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2014 34 Human papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co., Inc., H2 2014 35 Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2014 36 Human papillomavirus (HPV) Associated Cancer - Pipeline by Prima BioMed Ltd., H2 2014 37 Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2014 38 Human papillomavirus (HPV) Associated Cancer - Pipeline by THERAVECTYS SA, H2 2014 39 Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2014 40 Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2014 41 Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H2 2014 42 Assessment by Monotherapy Products, H2 2014 43 Assessment by Combination Products, H2 2014 44 Number of Products by Stage and Target, H2 2014 46 Number of Products by Stage and Mechanism of Action, H2 2014 48 Number of Products by Stage and Route of Administration, H2 2014 50 Number of Products by Stage and Molecule Type, H2 2014 52 Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H2 2014 97 Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2014 105
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.